Caroline Hroncich

An influx of millennial workers may have an impact on whether pharma manufacturers choose to implement IIoT technology.

The White House said President Trump will nominate Scott Gottlieb to the position of FDA commissioner.

Senator Chuck Grassley sent a letter to the Kaléo CEO questioning the drugs high listing price.

A new software technology, CRISPETa, is designed to assist in the deletion of non-protein coding sections of DNA.

Sarepta sold the priority review voucher for Exondys 51, a controversial treatment for Duchenne Muscular Dystrophy, to Gilead.

The Patent Trial and Appeal Board ruled in favor of the Broad Institute, allowing the company to keep patents for their CRISPR-Cas9 gene-editing technology.

A total of 166 biotech executives penned an open letter expressing concern over President Donald Trump’s executive order on immigration.

The medical cannabis producer has become compliant with EMA’s GMP standards.

The company will begin trials with its CBD chewing gum, CanChew Plus, for the treatment of irritable bowel syndrome.

A new report from HBM Partners said FDA new molecular entity approvals have dropped to 19 in 2016 from 45 in 2015.